Jay Bradner, president of the Novartis Institutes for Biomedical Research (NIBR), is retiring from the position after seven years in the role, and will be replaced by Merck & Co R&D executive ...

Then in October the company unveiled a major restructuring of its global R&D organisation, led from its headquarters in Basel, Switzerland and the Novartis Institutes for BioMedical Research (NIBR ...

The Series B round will help the Aditum Bio-backed startup fund two mid-stage clinical trials in people with alcohol and ...

Previously, Dr. Sellers directed cancer drug discovery and early cancer clinical development at the Novartis Institutes for ...

Sangamo Therapeutics, Inc.’s SGMO share price has dipped by 13.07%, which has investors questioning if this is right time to ...

Disclosures: Krishna G. Aragam receives sponsored research support from Sarepta Therapeutics and Bayer AG; he also reports a research collaboration with the Novartis Institutes for Biomedical Research ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much broader prostate cancer population. The new approval, which triples ...